# Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

> **NCT06355037** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 10 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Quercetin
- **DRUG:** Dasatinib
- **DRUG:** Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

## Key facts

- **NCT ID:** NCT06355037
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06355037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06355037, "Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06355037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*